Facebook Twitter LinkedIn Google Plus RSS

Cancer Genetics Inc. announces IPO pricing

By ,

Rutherford-based Cancer Genetics Inc., a diagnostics company focused on oncology tests and services, today announced the pricing of its initial public offering of 600,000 shares of its common stock at $10 per share.

The gross proceeds to Cancer Genetics from the initial public offering are expected to be $6 million. The offering is expected to close April 10, subject to customary closing conditions, the company announced.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!